Inovio Pharmaceuticals Inc vs Peloton Interactive Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Peloton Interactive Inc trades at $5.44 (market cap $2.46B). The key difference: Peloton Interactive Inc is far larger — about 31.3× Inovio Pharmaceuticals Inc's market cap, and Peloton Interactive Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | PTON | |
|---|---|---|
Market Cap | $78.55M | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $9.00 |
52-Week Low | $0.66 | $3.71 |
Enterprise Value | $49.56M | $2.96B |
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Peloton Interactive (PTON) trades at $5.45, down 1.09% on the day, reflecting ongoing investor caution despite achieving its first full-year net profit in fiscal 2026. The stock shows a bearish technical trend with key support at $5, while fundamentals highlight a challenging revenue decline to $2.4B in 2026, though net income turned positive at $63M. Analyst sentiment is mixed, with a 'Hold' consensus amid concerns over subscriber losses and a muted 2027 outlook.
The outlook remains cautious; profitability improvements and cost control offer a foundation, but persistent revenue declines and high debt levels pose significant risks. Investors should weigh the company's turnaround progress against competitive pressures and execution challenges in a saturated fitness market.
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →